From Casetext: Smarter Legal Research

In re Lorazepam Clorazepate Antitrust Litigation

United States District Court, D. Columbia
Jun 17, 2002
MDL - 1290 (TFH/JMF), Misc. No. 99ms276, CV 1:99-790 (TFH/JMF) CV 1:99-2228 (N.D. Ill.) (D.D.C. Jun. 17, 2002)

Opinion

MDL — 1290 (TFH/JMF), Misc. No. 99ms276, CV 1:99-790 (TFH/JMF) CV 1:99-2228 (N.D. Ill.)

June 17, 2002


ORDER


This matter is before the Court upon motion by Defendants Mylan Laboratories, Inc., Mylan Pharmaceuticals, Inc. and UDL Laboratories, Inc. to tile a Supplemental Memorandum In Opposition to Plaintiff's Motion to Quash (the "Supplemental Memorandum") under seal. Upon consideration of the motion and the record herein, the motion is hereby GRANTED. It is hereby ORDERED that the clerk shall receive and keep the pleading filed by Mylan under seal.


Summaries of

In re Lorazepam Clorazepate Antitrust Litigation

United States District Court, D. Columbia
Jun 17, 2002
MDL - 1290 (TFH/JMF), Misc. No. 99ms276, CV 1:99-790 (TFH/JMF) CV 1:99-2228 (N.D. Ill.) (D.D.C. Jun. 17, 2002)
Case details for

In re Lorazepam Clorazepate Antitrust Litigation

Case Details

Full title:IN RE LORAZEPAM CLORAZEPATE ANTITRUST LITIGATION ST CHARLES HOSPITAL and…

Court:United States District Court, D. Columbia

Date published: Jun 17, 2002

Citations

MDL - 1290 (TFH/JMF), Misc. No. 99ms276, CV 1:99-790 (TFH/JMF) CV 1:99-2228 (N.D. Ill.) (D.D.C. Jun. 17, 2002)